Fundraisings and IPOs

* On July 15, 2013, Oss-Q AB, a Swedish medtech company focusing on implants for bone replacement, has received SEK 13.7m through a rights issue and will now initiate a clinical trial with OssDsign Cranio PSI, its implant for skull reconstruction. Karolinska Development invested SEK 6.8m in the rights issue, increasing its ownership in OssDsign AB from 16% to 26%. After closing of a SEK 13.7m financing round, OssDsign has taken another important step by initiating a clinical multi-center study with its first product, OssDsign Cranio PSI. In addition to clinical outcome, the study evaluates quality of life and health economics. The first patients in the study have recently been treated at the Karolinska University Hospital in Stockholm.
In connection with these important advances, the company will change its name to OssDsign AB. Serious accidents and open brain surgery can result in large and complicated damage to the skull. In many cases, today\'s implant materials result in poor clinical outcomes, which is why OssDsign developed a new implant where biomaterials, mechanical properties and implant design are optimized precisely for these injuries. OssDsign develops a new bioceramic material with a chemical composition similar to bone. The company\'s strategy is to transform this technology into distinctively differentiated products for bone replacement and to build a niche company in orthopedics, starting with sales in skull surgery.